Information  X 
Enter a valid email address

EPIC/TIDM matching '0QNA'

Date
Time Source
Company
Announcement
24 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million
23 Feb 2021 4:47 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea launches a private placement of new shares by way of an accelerated bookbuilding
16 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
15 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces divestment of its Chinese R&D subsidiary to PHT International
12 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium
11 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor
10 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)
09 Feb 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million
11 Jan 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports preliminary 2020 revenue and portfolio progress
07 Jan 2021 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan
25 Nov 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China
06 Nov 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia
28 Oct 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer
26 Oct 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020
13 Oct 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer
12 Oct 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020
29 Sep 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer
28 Sep 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
22 Sep 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports data from poster presentations at ESMO Virtual Congress 2020
11 Aug 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19
07 Aug 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China
28 Jul 2020 6:22 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond
  6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces data presentations at ESMO Virtual Congress 2020
21 Jul 2020 6:00 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million
20 Jul 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)
17 Jul 2020 6:08 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds
  6:00 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million
15 Jul 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific
10 Jul 2020 6:00 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces the start of the offer period of its partial repurchase offer for its outstanding convertible bonds due 2022
30 Jun 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022
25 Jun 2020 6:00 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022
24 Jun 2020 7:36 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea successfully places CHF 125 million senior convertible bonds
  6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million
23 Jun 2020 6:00 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea enters into sale and leaseback agreement for corporate headquarters building
22 Jun 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cresemba® in Russia
28 May 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea provides corporate update
29 Apr 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces appointment of new Head of Global Quality Management
08 Apr 2020 5:55 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
27 Feb 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific
18 Feb 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports significant revenue growth from marketed products and pipeline progress for full-year 2019
23 Jan 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium
22 Jan 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer
10 Jan 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports total revenue exceeding guidance driven by higher than expected contributions from Cresemba® and Zevtera® in 2019
08 Jan 2020 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019
07 Jan 2020 9:47 am EQS Factsheet Edison Investment Research Lim (0QNA) Edison issues outlook on Basilea Pharmaceutica (BSLN)
16 Dec 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study
06 Dec 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million
30 Oct 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference
29 Oct 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports marketing authorization of antifungal Cresemba® in Brazil
30 Sep 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
27 Aug 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer
20 Aug 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019
13 Aug 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea starts phase 1/2 study with derazantinib in urothelial cancer
06 Aug 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)
01 Jul 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
03 Jun 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting
02 May 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada
12 Apr 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
10 Apr 2019 4:45 pm GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
19 Feb 2019 6:15 am GNW Factsheet Basilea Pharmaceutica AG (0QNA) Basilea reports strong revenue growth and significant pipeline progress for full-year 2018


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t